183 related articles for article (PubMed ID: 32299818)
1. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
4. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
5. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
[TBL] [Abstract][Full Text] [Related]
6. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
[TBL] [Abstract][Full Text] [Related]
8. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
9. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
[No Abstract] [Full Text] [Related]
12. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
[TBL] [Abstract][Full Text] [Related]
13. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
[TBL] [Abstract][Full Text] [Related]
14. Identification of
Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
Front Oncol; 2022; 12():981940. PubMed ID: 36568239
[TBL] [Abstract][Full Text] [Related]
15. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
[TBL] [Abstract][Full Text] [Related]
16. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
[TBL] [Abstract][Full Text] [Related]
17. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
Ni X; Xing Y; Sun X; Suo J
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
